BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
US |
|
Costco Wholesale Corp
NASDAQ:COST
|
US |
|
Xlife Sciences AG
SIX:XLS
|
CH |
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc., a beacon in the realm of niche biopharmaceutical innovations, has carved its path by focusing on the development of novel oral drugs that address rare and serious medical conditions. Anchored by its expertise in small molecule therapies, BioCryst operates at the intricate intersection of biology and chemistry, designing drugs that intervene in essential biological pathways. Its flagship product, ORLADEYO® (berotralstat), received a significant nod of approval when it was launched as the first oral, once-daily prophylactic treatment for hereditary angioedema (HAE). This rare condition, characterized by recurrent swelling attacks, previously had limited treatment options, often requiring cumbersome and painful injections. The oral nature of ORLADEYO filled a critical unmet need, propelling the company to a lucrative frontier within the pharmaceutical market.
Revenue generation for BioCryst is firmly rooted in the licensing and sale of its proprietary drugs. With ORLADEYO, the company has not only achieved a foothold in a specialty pharmaceutical market but also laid a foundation for sustainable financial growth. Through strategic pricing and distribution channels, supported by collaboration with global healthcare partners, BioCryst maximizes its market reach while focusing on adding to its pipeline with promising candidates in various stages of clinical development. Its approach is a careful blend of scientific innovation and business acumen, ensuring that the impacts of their breakthroughs are not only felt in prolonged patient lifespans but also reflected in the company’s bottom line.
BioCryst Pharmaceuticals Inc., a beacon in the realm of niche biopharmaceutical innovations, has carved its path by focusing on the development of novel oral drugs that address rare and serious medical conditions. Anchored by its expertise in small molecule therapies, BioCryst operates at the intricate intersection of biology and chemistry, designing drugs that intervene in essential biological pathways. Its flagship product, ORLADEYO® (berotralstat), received a significant nod of approval when it was launched as the first oral, once-daily prophylactic treatment for hereditary angioedema (HAE). This rare condition, characterized by recurrent swelling attacks, previously had limited treatment options, often requiring cumbersome and painful injections. The oral nature of ORLADEYO filled a critical unmet need, propelling the company to a lucrative frontier within the pharmaceutical market.
Revenue generation for BioCryst is firmly rooted in the licensing and sale of its proprietary drugs. With ORLADEYO, the company has not only achieved a foothold in a specialty pharmaceutical market but also laid a foundation for sustainable financial growth. Through strategic pricing and distribution channels, supported by collaboration with global healthcare partners, BioCryst maximizes its market reach while focusing on adding to its pipeline with promising candidates in various stages of clinical development. Its approach is a careful blend of scientific innovation and business acumen, ensuring that the impacts of their breakthroughs are not only felt in prolonged patient lifespans but also reflected in the company’s bottom line.
Revenue Growth: ORLADEYO revenue reached $601.8 million for 2025, up 38% year-over-year and 43% when excluding the now-divested Europe business.
Profitability: Operating profit hit a record $214 million, a 198% increase from the prior year, marking BioCryst's highest ever.
Guidance Maintained: 2026 ORLADEYO revenue is expected to be $625–$645 million, representing about 13% growth over 2025 (adjusted for Europe), with guidance unchanged.
Pipeline Progress: Phase III enrollment for Navenibart is progressing well, with a regulatory filing targeted for late 2027 and approval by late 2028.
Pediatric Launch: FDA approved ORLADEYO oral pellets for children aged 2 to under 12 in December 2025, with a launch underway and early but conservative revenue expectations for 2026.
Pricing Update: A 9% price increase for ORLADEYO was implemented in January 2026, with a net impact of about 4.5%.
Strong Cash Position: Ended 2025 with $337.5 million in cash and investments and secured a new $400 million financing facility.
Capital Discipline: Management emphasized focus on ROI, cost control, and maintaining profitability, especially following the European business sale.
